Physician profile
Dan Schuller
NPI 1467566042
$13,632.25
in general payments reported to CMS, 2019-2025
12 companies · $375 in 2025
The $375 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $11.37 · 2021: $198 · 2022: $277 · 2024: $88.60 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $447 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $446.61 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $11,631.64 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $1,050.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $245.33 | 2021-2025 | Ofev |
| United Therapeutics Corporation | $205.20 | 2022-2024 | |
| Verona Pharma, INC. | $125.00 | 2025 | Ohtuvayre |
| Merck Sharp & Dohme LLC | $108.18 | 2025 | Winrevair |
| Actelion Pharmaceuticals US, INC. | $99.99 | 2022 | |
| Dova Pharmaceuticals | $77.50 | 2021 | |
| Sobi, INC | $60.66 | 2022 | |
| Insmed, INC. | $17.38 | 2025 | Brinsupri |
| Smith+Nephew, INC. | $11.37 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dan Schuller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.